Global product engineering and lifecycle services company QuEST Global has developed an artificial intelligence (AI)-powered diagnostic solution to advance the screening capabilities for Covid-19 disease.

The company’s AI-powered solution will enable healthcare professionals to expedite the screening of Covid-19 patients with pneumonia symptoms.

QuEST Global hi-tech and digital global head Krish Kupathil said: “Since the fight against Covid-19 is all about faster screening and immediate isolation of maximum number of people, we aim to accelerate the screening time as much as possible.

“The AI-based solution will make radiography examinations much faster by leveraging modern image diagnostic systems.”

The AI-powered diagnostic solution is supported by Microsoft Azure Machine Learning platform

QuEST AI-powered diagnostic solution applies advanced deep learning models for the sorting and detection of chest X-rays of patients with the novel corona virus disease.

According to the company, the solution can be deployed on the cloud as a service with an accuracy of more than 95%.

The new diagnostic solution is supported by Microsoft Azure Machine Learning platform, which enables to develop and deploy on machine learning models in a secured manner.

QuEST’ medical devices engineering team has designed the new technology demonstrator using chest X-rays of healthy individuals, patients with symptoms of pneumonia and Covid-19.

The X-rays have been used to train and develop a deep neural network model, which could separate the radiological patterns of pneumonia related to Covid-19 and focus on the suspicious ones, enabling to rapidly screen the disease.

Microsoft Americas IoT and mixed reality sales general manager Michael Kuptz said: “In these unprecedented times, saving human lives is the ultimate goal, and technology can help. Microsoft’s collaborations with product engineering leaders like QuEST can go a long way to driving a more positive outcome.”

QuEST Global is a product engineering and lifecycle services partner to multiple companies in the aero engines, hi-tech, aerospace and defense, transportation (auto and rail), power and industrial, oil and gas, and medical devices industries.

In May, Royal Philips secured 510(k) clearance from the US Food and Drug Administration (FDA) for its wider range of ultrasound solutions to manage Covid-19-related lung and cardiac complications.